Screener
Sana Biotechnology SANA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - |
| Common stock, $0.0001 par value; 750,000 shares authorized; 269,817 and 266,732 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 27 | 27 |
| Additional paid-in capital | 2,015,441 | 2,009,845 |
| Accumulated other comprehensive income (loss) | (2) | 28 |
| Accumulated deficit | (1,896,226) | (1,849,016) |
| Total stockholders' equity | 119,240 | 160,884 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $373,593 | $416,890 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's total equity?
- Sana Biotechnology (SANA) reported total equity of $119.24M in Q1 2026.
- How has Sana Biotechnology's total equity changed year-over-year?
- Sana Biotechnology's total equity decreased by 43.0% year-over-year, from $209.08M to $119.24M.
- What is the long-term trend for Sana Biotechnology's total equity?
- Over 5 years (2020 to 2025), Sana Biotechnology's total equity has grown at a -17.5% compound annual growth rate (CAGR), from -$421.18M to $160.88M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Sana Biotechnology's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude